Intelliseq
David Hanna has a strong background in sales and business development within the biotechnology industry. David currently serves as the Chief Commercial Officer (CCO) at Intelliseq since 2023. Prior to this, they worked at Thermo Fisher Scientific from 2019 to 2023, where they held the position of Director of Global Sales and Business Development, overseeing the use of microarrays for preventive/predictive medicine programs. David was responsible for developing a network of service lab and clinical reporting partners to provide integrated healthcare solutions.
Before joining Thermo Fisher Scientific, Hanna worked at Affymetrix for a significant portion of their career, from 2002 to 2019. David held various roles during their time at the company, including Director of Genotyping Sales for the Americas region, Senior District Sales Manager for the Southeast, and National Accounts Manager. David'sresponsibilities included achieving sales targets and managing key accounts.
Prior to their tenure at Affymetrix, Hanna worked at Incyte Genomics as a Key Account Executive/Client Business Manager from 2001 to 2002. David also served as a Sales Engineer at Packard BioScience (now part of Perkin Elmer) from 1999 to 2001 and as a Technical Sales Representative at Stratagene from 1996 to 1999.
David Hanna attended The University of Texas at Austin, where they obtained their BA in Biochemistry. After completing their undergraduate studies, they pursued further education at The University of Georgia, where they earned their Ph.D. in Biochem/Genetics. Following their doctoral degree, David Hanna conducted postdoctoral research at The Johns Hopkins University, focusing on Genetics.
This person is not in any teams
This person is not in any offices
Intelliseq
Intelliseq is a genome informatics company developing bioinformatics tools for diagnostics, therapy, and prevention based on genetic data. Currently bioinformatics systems in laboratories are not ready for genomics at scale. The analysis process of already sequenced genomes is now mostly expensive and labor-intensive. In response to this problemthe company created a cloud-based platform called IntelliseqFlow that allows for automated bioinformaticianless generation of result reports that accelerates the entire diagnostic process and reduces the costs that the laboratory had to deal with so far. IntelliseqFlow translates raw DNA data into final reports automatically, making the analysis step fast, simple, cost-effective and user-friendly. Allows users to choose ready-to-use workflows for PGx, Germline Disorders, Somatic Cancer, and Polygenic Risk Scoring all wrapped-up in one user-friendly platform. It comprises AI-based algorithms, easy to operate pipelines, customized workflows, and APIs that make it simple to integrate our engine with laboratory information systems.The company was established in 2014 by a group of scientists fascinated with pharmacogenomics and transcriptomics. Intelliseq’s products are currently being used by laboratories in Asia, Europe, and the US.